Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two o...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hidenori, Iwasaki, Yoshinobu, Watanabe, Takayasu, Ichinose, Naoki, Okada, Yasusei, Oiwa, Akito, Kobayashi, Takehiro, Moriya, Mariko, Oda, Toshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441042/
https://www.ncbi.nlm.nih.gov/pubmed/32829044
http://dx.doi.org/10.1016/j.ijid.2020.08.047
_version_ 1783573231142174720
author Takahashi, Hidenori
Iwasaki, Yoshinobu
Watanabe, Takayasu
Ichinose, Naoki
Okada, Yasusei
Oiwa, Akito
Kobayashi, Takehiro
Moriya, Mariko
Oda, Toshimi
author_facet Takahashi, Hidenori
Iwasaki, Yoshinobu
Watanabe, Takayasu
Ichinose, Naoki
Okada, Yasusei
Oiwa, Akito
Kobayashi, Takehiro
Moriya, Mariko
Oda, Toshimi
author_sort Takahashi, Hidenori
collection PubMed
description The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured.
format Online
Article
Text
id pubmed-7441042
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-74410422020-08-21 Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition Takahashi, Hidenori Iwasaki, Yoshinobu Watanabe, Takayasu Ichinose, Naoki Okada, Yasusei Oiwa, Akito Kobayashi, Takehiro Moriya, Mariko Oda, Toshimi Int J Infect Dis Case Report The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020-11 2020-08-21 /pmc/articles/PMC7441042/ /pubmed/32829044 http://dx.doi.org/10.1016/j.ijid.2020.08.047 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Takahashi, Hidenori
Iwasaki, Yoshinobu
Watanabe, Takayasu
Ichinose, Naoki
Okada, Yasusei
Oiwa, Akito
Kobayashi, Takehiro
Moriya, Mariko
Oda, Toshimi
Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
title Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
title_full Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
title_fullStr Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
title_full_unstemmed Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
title_short Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
title_sort case studies of sars-cov-2 treated with favipiravir among patients in critical or severe condition
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441042/
https://www.ncbi.nlm.nih.gov/pubmed/32829044
http://dx.doi.org/10.1016/j.ijid.2020.08.047
work_keys_str_mv AT takahashihidenori casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT iwasakiyoshinobu casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT watanabetakayasu casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT ichinosenaoki casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT okadayasusei casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT oiwaakito casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT kobayashitakehiro casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT moriyamariko casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition
AT odatoshimi casestudiesofsarscov2treatedwithfavipiraviramongpatientsincriticalorseverecondition

Ejemplares similares